The shares of this agrochemical company gained up to 4.6 percent after receiving new purchase orders of approx. Rs. 31,06,500 from three Client Companies for the supply of various Agrochemicals.
With a market capitalization of Rs 47.48 Crores. Aristo Bio-Tech & Lifescience Ltd, On Tuesday, The shares were trading at Rs 69.75 a share, an increase of 0.22 percent from the previous closing price.
Aristo Bio-Tech & Lifescience Ltd. has received new purchase orders for the supply of various agrochemicals worth approximately Rs. 31,06,500, which are divided into three parts by three domestic clients: Rs. 27,66,000, Rs. 1,45,500, and Rs. 1,95,000. This information is based on the company’s exchange filing.
The company’s growth will be aided by government initiatives to promote the agriculture sector. Government subsidies to farmers, as well as an abundance of electricity and water, will support the growth of the agriculture sector. Keeping up the advancement in research and development, producing new products.
Third in Asia and the sixth-largest producer of agrochemicals worldwide is the Indian chemical sector. India ranks fourth in the world for agrochemical production.
India comes in eighth place for imports and 14th place for exports of chemical products. With a predicted compound annual growth rate (CAGR) of 9.3%, the Indian chemical industry, valued at US$ 232 billion in 2022, is projected to grow to US$ 304 billion by 2025.
Looking into the company’s performance, Aristo Bio-Tech & Lifescience Ltd’s revenue increased by 3.1 percent from Rs 129 Crore in Q2FY23 to Rs 133 Crore in Q2FY24. During the same period, net profit is constant at Rs 3 crore.
An agrochemical company is Aristo Bio-Tech and Lifescience Limited. Their primary activities involve producing, creating, distributing, wrapping, and providing contract work services for a range of pesticides.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
